Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:MOR NASDAQ:PCRX NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$36.80-0.4%$33.37$25.17▼$39.56$6.13B0.312.15 million shs907,753 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APCRXPacira BioSciences$23.35-0.6%$23.47$18.80▼$27.64$918.78M0.32618,742 shs857,902 shsRCKTRocket Pharmaceuticals$2.96-4.8%$3.76$2.19▼$6.43$323.21M0.522.28 million shs2.11 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-1.81%+8.52%+15.32%+20.54%MORMorphoSys0.00%0.00%0.00%0.00%0.00%PCRXPacira BioSciences0.00%+3.14%-7.93%+0.56%-10.67%RCKTRocket Pharmaceuticals0.00%-8.92%-19.57%-21.69%-55.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$36.80-0.4%$33.37$25.17▼$39.56$6.13B0.312.15 million shs907,753 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/APCRXPacira BioSciences$23.35-0.6%$23.47$18.80▼$27.64$918.78M0.32618,742 shs857,902 shsRCKTRocket Pharmaceuticals$2.96-4.8%$3.76$2.19▼$6.43$323.21M0.522.28 million shs2.11 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-1.81%+8.52%+15.32%+20.54%MORMorphoSys0.00%0.00%0.00%0.00%0.00%PCRXPacira BioSciences0.00%+3.14%-7.93%+0.56%-10.67%RCKTRocket Pharmaceuticals0.00%-8.92%-19.57%-21.69%-55.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.76Moderate Buy$45.4023.37% UpsideMORMorphoSys 0.00N/AN/AN/APCRXPacira BioSciences 2.29Hold$29.4025.91% UpsideRCKTRocket Pharmaceuticals 2.39Hold$11.54289.81% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, ALKS, RCKT, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026PCRXPacira BioSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/14/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026ALKSAlkermes Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $48.005/11/2026ALKSAlkermes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/11/2026RCKTRocket Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/6/2026ALKSAlkermes UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $48.005/6/2026ALKSAlkermes Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$43.00 ➝ $44.005/6/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.005/1/2026PCRXPacira BioSciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$22.00 ➝ $24.005/1/2026PCRXPacira BioSciences Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.004/27/2026ALKSAlkermes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.48B4.16$1.67 per share21.98$10.51 per share3.50MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17PCRXPacira BioSciences$726.41M1.26$3.86 per share6.05$16.62 per share1.40RCKTRocket PharmaceuticalsN/AN/AN/AN/A$2.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$241.66M$0.9040.8966.91N/A9.78%9.26%5.66%7/28/2026 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/APCRXPacira BioSciences$7.03M$0.12194.608.75N/A0.70%10.24%5.47%8/4/2026 (Estimated)RCKTRocket Pharmaceuticals-$223.12M-$1.87N/AN/AN/AN/A-69.61%-58.63%8/6/2026 (Estimated)Latest PCRX, ALKS, RCKT, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026RCKTRocket Pharmaceuticals-$0.41-$0.42-$0.01-$0.42$4.47 millionN/A4/30/2026Q1 2026PCRXPacira BioSciences$0.61$0.60-$0.01$0.07$171.80 million$177.38 million2/26/2026Q4 2025ALKSAlkermes$0.43$0.29-$0.14$0.29$380.44 million$384.55 million2/26/2026Q4 2025PCRXPacira BioSciences$0.85$0.57-$0.28$0.04$201.93 million$196.87 million2/26/2026Q4 2025RCKTRocket Pharmaceuticals-$0.42-$0.38+$0.04-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermes0.852.271.70MORMorphoSys4.981.381.38PCRXPacira BioSciences0.564.733.35RCKTRocket Pharmaceuticals0.086.126.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%MORMorphoSys18.38%PCRXPacira BioSciences99.73%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.59%MORMorphoSys0.05%PCRXPacira BioSciences6.40%RCKTRocket Pharmaceuticals21.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionablePCRXPacira BioSciences72039.35 million36.83 millionOptionableRCKTRocket Pharmaceuticals240109.19 million85.94 millionOptionablePCRX, ALKS, RCKT, and MOR HeadlinesRecent News About These CompaniesRocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?May 20, 2026 | finance.yahoo.comRocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6MMay 18, 2026 | finance.yahoo.comRocket Pharmaceuticals (NASDAQ:RCKT) Upgraded at Wall Street ZenMay 16, 2026 | americanbankingnews.comInsider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,361 Shares of StockMay 15, 2026 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from BrokeragesMay 13, 2026 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by AnalystsMay 13, 2026 | marketbeat.comLifesci Capital Analysts Raise Earnings Estimates for RCKTMay 12, 2026 | marketbeat.comSarbani Chaudhuri Sells 17,650 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) StockMay 12, 2026 | insidertrades.comRCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in FocusMay 11, 2026 | zacks.comRocket Pharmaceuticals (NASDAQ:RCKT) Receives "Buy" Rating from Chardan CapitalMay 11, 2026 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings ResultsMay 9, 2026 | marketbeat.comRocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI)April 29, 2026 | theglobeandmail.comRocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherApril 28, 2026 | joplinglobe.comJAnalysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)April 16, 2026 | theglobeandmail.comRCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseMarch 30, 2026 | zacks.comWhy Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADIMarch 29, 2026 | insidermonkey.comRocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 TranscriptMarch 27, 2026 | seekingalpha.comRocket Pharmaceuticals secures FDA approval for gene therapy KRESLADIMarch 27, 2026 | proactiveinvestors.caPRocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)March 27, 2026 | joplinglobe.comJRocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future ProductsMarch 27, 2026 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026PCRX, ALKS, RCKT, and MOR Company DescriptionsAlkermes NASDAQ:ALKS$36.80 -0.15 (-0.41%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$36.79 -0.01 (-0.03%) As of 05/22/2026 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 05/22/2026MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Pacira BioSciences NASDAQ:PCRX$23.35 -0.13 (-0.55%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$23.33 -0.02 (-0.09%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Rocket Pharmaceuticals NASDAQ:RCKT$2.96 -0.15 (-4.82%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.01 +0.05 (+1.69%) As of 05/22/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
